| 摘要: |
| 目的 介绍西地尼布的多种抗肿瘤作用临床研究进展。方法 检索近年来国内外相关的文献报道，对西地尼布用于卵巢癌、实体瘤、胆道癌、肾细胞癌、前列腺癌、宫颈癌和结肠癌这七大领域的临床试验进行综述。结果 西地尼布是一种强效的血管内皮生长因子受体抑制剂，大量临床试验资料表明它有潜力用于各种肿瘤。药动学研究显示它口服给药，每日1次，用药方便，且毒性反应与其他血管内皮生长因子受体抑制剂相似。结论 熟悉西地尼布的临床应用，对更好的开发西地尼布具有深远意义。 |
| 关键词: 西地尼布 AZD2171 血管内皮生长因子受体抑制剂 卵巢癌 |
| DOI：10.13748/j.cnki.issn1007-7693.2017.01.033 |
| 分类号:R284.1；R917.101 |
| 基金项目: |
|
| Clinical Advances of Anti-tumor Effects of Cediranib |
|
JIN Yanfen1, SHEN Wei2
|
|
1.Hangzhou Huadong Medicine Group Pharmaceutical Research Institute Co., Ltd., Hangzhou 310011, China;2.Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd., Hangzhou 310011, China
|
| Abstract: |
| OBJECTIVE To introduce kinds of cediranib's antitumor effects in clinic. METHODS According to the correlative reports in recent years, clinical trial of the seven areas of ovarian cancer, solid tumors, biliary tract cancer, renal cell carcinoma, prostate cancer, cervical cancer and colon cancer were reviewed. RESULTS Cediranib was a potent inhibitor of VEGFR, datas from clinical studies of cediranib suggested its potential anti-tumor effect. Pharmacokinetic studies showed that it was oral administration, once daily, conveniently, and it's toxicity was similar to other VEGFR inhibitors. CONCLUSION Familiar with the clinical application of cediranib, has profound significance for the development of better cediranib. |
| Key words: cediranib AZD2171 VEGFR inhibitors ovarian cancer |
